



3rd April 2020

BSE LIMITED Phiroze Jeejeebhoy Towers Dalal Street, Mumbai – 400001 Scrip Code: BSE – AJANTPHARM 532331	National Stock Exchange of India, Exchange Plaza, 5 th Floor, Plot no. C/1, G Block, Bandra Kurla Complex, Bandra (East), Mumbai – 400 051 Scrip Code: NSE AJANTPHARM EQ
--	--

Sub: Press Release

Dear Sir/Madam,

Please find enclosed herewith our press release titled “**Ajanta Pharma commits Rs. 6 crore to fight COVID-19 pandemic**” which we will be releasing after sending this letter to you.

We request you to kindly take the same on records.

Yours faithfully,

GAURANG SHAH

AVP - Legal & Company Secretary

Encl.: a/a

Press Release**Ajanta Pharma commits Rs. 6 crore to fight COVID-19 pandemic**

Mumbai, 3rd April, 2020: Ajanta Pharma commits Rs. 6 crore to fight COVID-19 pandemic. From that Rs 2 cr. has been directly contributed to Prime Minister CARES Fund and the rest Rs. 4 cr. is being spent on the below activities:

- Providing Ventilators, Thermal Thermometers, sanitizers and protective gears such as Latex Gloves, Gamex Gloves, N-95 Masks, PPE Kits, etc. to Government of Maharashtra, Brihanmumbai Municipal Corporation and other agencies.
- Distribution of food grains to migrant labourers and daily wage earners across different locations.
- Providing medicines free of cost to various authorities and organization.

Ajanta Pharma is firmly standing with Govt. of India and State Governments in its efforts to overcome this pandemic. We also fully recognise and appreciate their prompt and tireless efforts to contain the spread of COVID-19, while ensuring the availability of the essentials to the nation.

We are also grateful from the core of our heart to the entire medical fraternity for their selfless efforts to protect the humanity.

Ajanta Pharma Ltd. continues to strive hard to maintain un-interrupted supply of life-saving drugs in India and across the world with the help of Ajantaites, who are committed to play their role during this global crisis.

Talking about the contribution Mr. Yogesh Agrawal, Managing Director, Ajanta Pharma said:

“Ajanta’s mission to serve global healthcare needs through empathy, innovation and technology has come to the fore with the Company standing with the government and patients to overcome the humanitarian crisis triggered by the global spread of COVID-19. We salute the doctors, medical staffs and government authorities working selflessly for the cause and promise to tirelessly work towards ensuring availability of essential medicines.”

About Ajanta Pharma Limited

Ajanta Pharma is a speciality pharmaceutical formulation company having branded generic business in India and emerging markets, generic business in US and institution business in Africa. Many of company’s products are 1st to market and are leading in their sub-therapeutic segments.

Company’s state of the art R&D centre is located at Mumbai, having a team of 650+ scientists. Company has 8 world class manufacturing facilities located in different parts of India and Mauritius.

For last 10 financial years, company has posted healthy performance with its consolidated total income growing at 20% CAGR and net profit at 31% CAGR.

For more details visit www.ajantapharma.com

For regular updates follow us on twitter– www.twitter.com/ajantapharmaltd

For specific queries, contact:

Rajeev Agarwal Tel: +91 22 66061377 Email: rajeev.agarwal@ajantapharma.com

Abhineet Kumar Tel: +91 22 66061814 Email: abhineet.kumar@ajantapharma.com

Reuters: AJPH.NS, Bloomberg: AJP:IN, NSE: AJANTPHARM, BSE: 532331
Corporate Identity Number (CIN): L24230MH1979PLC022059